Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States.
FAIL · Does not pass the screen
27.67 USD
Screen close, 2026-10-02 · not a live quote
Screened 2026-10-02 · the tape above runs as of 07:26 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 27.67 against the desk's fair-value range, base estimate 70.00, over the last year.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price27.67 USD
Fair value70.00
Ethical score70.0/100
Our investment reviews on this name
2026-10-02Read Distribution35.00-20.9% to today ✓
2026-08-31Read Accumulation49.35-43.9% to today
2026-07-31Read Markup48.48-42.9% to today
2026-07-02Read Markdown42.93-35.5% to today ✓
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Structure Therapeutics Inc. holds its Distribution at $27.67. The statistical read favours the sellers, held for 97 days.
As held on the ledger · 2026-10-02
Phase
Distribution · caution
Quantitative state
The statistical read favours the sellers, held for 97 days
Price at the screen
$27.67
Valuation
N/A trailing · -13.10 forward price to earnings
Values screen
FAIL· score 70.0
Beta
-1.52
The Workings
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
0.41%
Below 33%
Interest-bearing debt is just 0.4% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
40.82%
Below 33%
Interest-bearing cash and securities are 40.8% of assets, above the one-third limit.
Fail
Receivables
56.80%
Below 49%
Money owed to the company is 56.8% of assets, above the 49% limit.
Fail
Revenue purity
Excluded
Below 5%
of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Structure Therapeutics's business is fine, but its cash and interest-bearing securities are about 41% of its assets, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-04. It updates when the underlying figures move, and past reads are kept below.
Fair value range in USD, drawn from the 2026-10-02 screen. The gold marker is the market price at the same screen. A 100.0% margin of safety to the base estimate.
Third-party analyst targets: 15 covering, consensus None. The average target sits +265% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-02 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Clinical biotech with no profits or data
Imagine handing cash to a lab team that has never turned a profit and cannot show basic financial ratios. Structure Therapeutics is exactly that, a clinical stage player developing oral molecules for chronic disease. The opportunity rating sits at none, the ethical screen returns insufficient data, and with zero profit margin plus negative fifteen percent return on equity the business offers nothing to anchor a position.
Forward earnings sit at a negative twenty five times multiple while the share price of forty eight dollars trades at half the analyst median target. That gap looks tempting only until the complete absence of moat data and financial ratios is factored in. Without those foundations any apparent margin of safety remains an accounting mirage.
Clinical trials can fail at any stage, cash burn is constant, and the ethical gaps alone rule out further work. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
GPCR trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from accumulation to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 29.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 89%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (16 analysts) rates it none, with a mean price target of $106.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 1.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 89%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (16 analysts) rates it none, with a mean price target of $106.
2026-07-31Markup · changed$48.48+12.9%Entry 4
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 12.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 89%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (16 analysts) rates it none, with a mean price target of $106.
2026-07-18Markdown$42.93+0.0%Entry 3
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 89%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (16 analysts) rates it none, with a mean price target of $106.
2026-07-03Markdown$42.93+0.0%Entry 2
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Markdown$42.93Entry 1
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
